이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HOB Biotech GroupLtd 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

John Li

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.1yrs
CEO 소유권	56.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	7.1yrs

최근 관리 업데이트

Recent updates

Subdued Growth No Barrier To HOB Biotech Group Corp.,Ltd's (SHSE:688656) Price

Jul 04

HOB Biotech GroupLtd's (SHSE:688656) Earnings Are Weaker Than They Seem

May 06

Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 25%

Mar 08

CEO

John Li (61 yo)

7.1yrs

테뉴어

CN¥1,665,800

보상

Mr. John Li serves as the Chairman & General Manager of HOB Biotech Group Co., Ltd and serves its Director since July 19, 2017. Mr. Li founded HOB Biotech in 2007. Mr. Li worked for multi-national corporat...

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Li	Chairman & GM	7.1yrs	CN¥1.67m	55.96% CN¥ 701.3m
Qingxin Liu	Director & Deputy GM	no data	CN¥2.12m	0.00032% CN¥ 4.0k
Kai Wang	Vice Chairman of the Board	10.8yrs	CN¥1.65m	0.042% CN¥ 525.1k
Jun Feng Zhou	Director	7.1yrs	CN¥642.20k	데이터 없음
Fei Ma	Supervisor	7.1yrs	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 688656 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.

HOB Biotech GroupLtd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

HOB Biotech Group Corp.,Ltd, Annual General Meeting, May 17, 2024

Recent updates

Investor sentiment improves as stock rises 16%

Subdued Growth No Barrier To HOB Biotech Group Corp.,Ltd's (SHSE:688656) Price

HOB Biotech Group Corp.,Ltd to Report First Half, 2024 Results on Aug 27, 2024

HOB Biotech GroupLtd's (SHSE:688656) Earnings Are Weaker Than They Seem

Full year 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.66 in FY 2022)

HOB Biotech Group Corp.,Ltd, Annual General Meeting, May 17, 2024

Investor sentiment deteriorates as stock falls 18%

HOB Biotech Group Corp.,Ltd to Report Q1, 2024 Results on Apr 29, 2024

HOB Biotech Group Corp.,Ltd (SHSE:688656) announces an Equity Buyback for CNY 30 million worth of its shares.

Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 25%

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Full year 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in FY 2022)

Investor sentiment deteriorates as stock falls 17%

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.14 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.17 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.66 (vs CN¥1.40 in FY 2021)

Investor sentiment improves as stock rises 16%

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.47 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.27 (vs CN¥0.51 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥1.40 (vs CN¥1.20 in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.47 (vs CN¥0.42 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.51 (vs CN¥0.42 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.20 (vs CN¥1.35 in FY 2019)

Investor sentiment deteriorated over the past week

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령